肥胖与炎症性肠病患者对英夫利昔单抗应答的关联:临床试验个体参与者数据汇总分析
基于YODA项目四项英夫利昔单抗治疗炎症性肠病临床试验的个体参与者数据汇总分析,纳入1205例患者(平均年龄37岁,男性51.6%,肥胖14%)。肥胖与临床缓解、临床应答及黏膜愈合的 odds 均无显著关联,结论在疾病类型和试验设计分层中一致。
要点
- 肥胖与英夫利昔单抗治疗炎症性肠病的临床缓解无显著关联(肥胖 vs 非肥胖:校正OR 0.93,95%CI 0.47-1.46)。
- BMI最高四分位与最低四分位相比,临床缓解、临床应答及黏膜愈合的校正OR均无显著差异。
- 结果在克罗恩病与溃疡性结肠炎、诱导与维持治疗分层中一致。
核心结论
- 基于个体参与者数据汇总分析,肥胖与炎症性肠病患者对英夫利昔单抗应答不佳无关。
- 作者认为,未来需开展研究探讨肥胖与固定剂量疗法之间的关联。
研究设计与样本
- 采用Yale Open Data Access(YODA)项目数据,对四项英夫利昔单抗治疗成人炎症性肠病临床试验(ACCENT-I、SONIC、ACT-1和ACT-2)的个体参与者数据进行汇总分析。
- 共纳入1205例接受英夫利昔单抗治疗的患者,平均年龄37岁,男性51.6%,肥胖占14%。
- 按体重指数(BMI)≥30 kg/m2定义为肥胖 vs 非肥胖,并按入组时BMI或体重四分位分组。
- 主要结局为临床缓解(克罗恩病活动指数[CDAI]<150或儿童CDAI<10,Mayo临床评分<3);次要结局为临床应答和黏膜愈合。
- 采用多变量logistic回归分析,校正性别、吸烟、疾病活动度及合并泼尼松和/或免疫调节剂。
主要发现
- 肥胖 vs 非肥胖与临床缓解的校正OR为0.93(95%CI 0.47-1.46)。
- BMI最高四分位(Q4)vs 最低四分位(Q1)与临床缓解的校正OR为0.94(95%CI 0.61-1.47),趋势P值=0.97。
- Q4 vs Q1与临床应答的校正OR为0.84(95%CI 0.52-1.35),P=0.45。
- Q4 vs Q1与黏膜愈合的校正OR为1.13(95%CI 0.55-2.34),P=0.95。
- 上述结果在基于疾病类型(克罗恩病和溃疡性结肠炎)和试验设计(诱导和维持治疗)的分层中一致。
关键数值与推荐
- 肥胖定义:BMI≥30 kg/m2。
- 临床缓解定义:CDAI<150或儿童CDAI<10,Mayo临床评分<3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为,未来需开展研究探讨肥胖与固定剂量疗法之间的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether obesity may affect response to infliximab, we conducted an individual participant data pooled analysis using data from clinical trials of infliximab in inflammatory bowel diseases (IBD), using the Yale Open Data Access (YODA) Project. METHODS: We analyzed individual participant data from four clinical trials of infliximab in adults with IBD (ACCENT-I, SONIC, ACT-1, and -2). Patients were categorized as obese (body mass index [BMI] ≥ 30 kg/m2) vs. non-obese, and by quartiles based on BMI or weight at time of trial entry. Primary outcome was clinical remission (Crohn's disease activity index [CDAI] < 150 or pediatric CDAI <10, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing. Multivariable logistic regression analysis was performed, after adjusting for sex, smoking, disease activity, and concomitant prednisone and/or immunomodulators. RESULTS: We included 1205 infliximab-treated patients (mean age 37 years, 51.6% males, 14% obese). Obesity was not associated with odds of achieving clinical remission (obese vs. non-obese: adjusted OR, 0.93 [95% CI, 0.47-1.46]; Q4 vs. Q1: aOR, 0.94 [0.61-1.47], p-value for trend = 0.97), clinical response (Q4 vs. Q1: aOR, 0.84 [0.52-1.35], p = 0.45) or mucosal healing (Q4 vs. Q1: aOR, 1.13 [0.55-2.34], p = 0.95). These results were consistent across strata based on disease type (Crohn's disease and ulcerative colitis) and trial design (induction and maintenance therapy). CONCLUSIONS: Based on individual participant data pooled analysis, obesity is not associated with inferior response to infliximab in patients with IBD. Future studies examining the association between obesity and fixed-dose therapies are warranted.
引用
- Singh S, Proudfoot J, Xu R, et al. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018. PMID: 29867171. doi:10.1038/s41395-018-0104-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。